Evidence map›Paper›PMID 41616583›Full record

ArticleNuclear medicine and biology

Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer.

Meltem Ocak, Kanishka Sikligar, Michael Pun, Khanh-Van Ho, Xiaoxi Ling, Valerie N Carroll, Jaime Simón, Melody D Fulton, Hunter N Bomba, Clifford E Berkman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meltem OcakMolecular Imaging and Theranostics Center, Columbia, MO, 65211, USA.
Kanishka SikligarMolecular Imaging and Theranostics Center, Columbia, MO, 65211, USA; Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA.
Michael PunMolecular Imaging and Theranostics Center, Columbia, MO, 65211, USA; Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA.
Khanh-Van HoMolecular Imaging and Theranostics Center, Columbia, MO, 65211, USA; Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA.
Xiaoxi LingDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Valerie N CarrollMolecular Imaging and Theranostics Center, Columbia, MO, 65211, USA.
Jaime SimónIsoTherapeutics Group, Angleton, TX, 77515, USA.
Melody D FultonCancer Targeted Technology, LLC, Woodinville, WA, 8072, USA; Department of Chemistry, Washington State University, Pullman, WA, 99164, USA.
Hunter N BombaCancer Targeted Technology, LLC, Woodinville, WA, 8072, USA.
Clifford E BerkmanCancer Targeted Technology, LLC, Woodinville, WA, 8072, USA; Department of Chemistry, Washington State University, Pullman, WA, 99164, USA.
Beatrice C Langton-WebsterCancer Targeted Technology, LLC, Woodinville, WA, 8072, USA. Electronic address: bealw@cancertargetedtechnology.com.
Carolyn J AndersonMolecular Imaging and Theranostics Center, Columbia, MO, 65211, USA; Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Department of Radiology, University of Missouri, Columbia, MO, 65211, USA; Ellis Fischel Cancer Center, Columbia, MO, 65211, USA. Electronic address: carolyn.j.anderson@missouri.edu.

Funding

Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted RadiotherapyR44CA257799 · NCI · CANCER TARGETED TECHNOLOGY, LLC · PI BOMBA, HUNTER NICOLE · 2021 to 2022
$2.0M
NCI NIH HHS R44 CA257799
6 · The paper itself

Abstract

backgroundCTT1403 (

methodsCTT2001 was synthesized and radiolabeled with

resultsCTT1403 synthesized via the one-step method demonstrated cellular uptake and internalization in PC3-PIP cells, as well as in vivo biodistribution in PC3-PIP tumor-bearing mice, that were comparable to those of the two-step-labeled product. The one-step procedure was successfully automated on the Trasis All-in-One synthesizer, producing CTT1403 with a radiochemical yield of 86.5 ± 4.27% (n = 3), a molar activity of 30.3 ± 1.11 MBq/nmol, and a radiochemical purity of 97.6 ± 0.80% (n = 3) in a total synthesis time of 38 min. The final product remained stable for at least 24 h at -4 °C and -20 °C.

conclusionsThe one-step radiolabeling method yields CTT1403 that is biologically equivalent to the two-step product and can be reliably produced using fully automated synthesis. This streamlined, efficient, and reproducible approach supports routine clinical manufacturing of CTT1403.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIIsotope LabelingProstatic NeoplasmsRadioisotopesAnimalsAutomationCell Line, TumorHumansLutetiumMaleMiceMolecular Targeted TherapyTissue DistributionAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177Radioisotopes(177)LuProstate cancerPSMARadiotherapy

Identifiers

PMID41616583
PMCPMC12978687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.